The Technical Analyst
Regenxbio Inc [RGNX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Regenxbio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.88% $16.04
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 785.84 mill |
| EPS: | -6.02 |
| P/E: | -2.66 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 48.99 mill |
| Avg Daily Volume: | 0.747 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.66 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.45x |
| Company: PE -2.66 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 14.61 - 17.47 ( +/- 8.90%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Mills Kenneth T. | Buy | 15 000 | Common Stock |
| 2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Common Stock |
| 2024-04-15 | Mills Kenneth T. | Sell | 15 000 | Stock Options (Right to Buy) |
| 2024-03-19 | Vasista Vittal | Buy | 20 041 | Common Stock |
| 2024-03-19 | Vasista Vittal | Sell | 20 041 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 56.32 |
| Last 99 transactions |
| Buy: 2 306 609 | Sell: 467 606 |
Forecast:
16:00 - $16.04
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.04
Forecast 2: 16:00 - $16.04
Forecast 3: 16:00 - $16.04
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.04 (0.88% ) |
| Volume | 0.334 mill |
| Avg. Vol. | 0.747 mill |
| % of Avg. Vol | 44.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RGNX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $16.22 | N/A | Active |
|---|
RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest Press Releases
2024-04-24 07:05:00 - Press Release
Regenxbio To Participate In Chardan's 8th Annual Genetic Medicines And Cell Therapy Manufacturing Summit
Rockville, md. , april 24, 2024 /prnewswire/ -- regenxbio inc. (nasdaq: rgnx) today announced it will participate in chardan's 8th annual genetic medicines and cell therapy manufacturing summit on monday, april 29, 2024.
2024-03-28 07:05:00 - Press Release
Regenxbio Announces Lancet Publication Of Phase I/iia Study Evaluating Abbv-rgx-314 As A One-time Gene Therapy For Wet Amd
A single abbv-rgx-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-vegf treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet amd due to the treatment burden of chronic anti-vegf injections patients who received therapeutic doses resulted in stable or improved vision and retinal anatomy up to 2 years additional long-term follow-up data has demonstrated durable treatment effect, with stable or improved vision, up to 4 years enrollment is on track in pivotal trials of abbv-rgx-314 in wet amd that are expected to support global regulatory submissions in late 2025 through the first half of 2026 rockville, md...
2024-03-27 16:05:00 - Press Release
Regenxbio To Participate In Cantor Fitzgerald's Virtual Dmd And Other Dystrophy Days
Rockville, md. , march 27, 2024 /prnewswire/ -- regenxbio inc. (nasdaq: rgnx) today announced it will participate in cantor fitzgerald's virtual dmd and other dystrophy days on wednesday, april 3, 2024.
2024-03-11 07:05:00 - Press Release
Regenxbio To Participate In Upcoming Investor Conferences
Rockville, md. , march 11, 2024 /prnewswire/ -- regenxbio inc. (nasdaq: rgnx) today announced it will participate the following upcoming investor conferences: leerink partners 2024 global biopharma conference date: tuesday, march 12, 2024 location: miami, fl 1x1 investor meetings only barclays 26th annual global healthcare conference fireside chat: wednesday, march 13, 2024 at 4:05 p.m.
2024-03-06 23:20:00 - Press Release
Regenxbio Announces Pricing Of Upsized Public Offering Of Common Stock And Pre-funded Warrants
Rockville, md. , march 6, 2024 /prnewswire/ -- regenxbio inc. (nasdaq: rgnx) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, today announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting discounts and commissions.
Latest News
2024-03-11 07:05:00 - PRNewsWire
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md. , March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Leerink Partners 2024 Global Biopharma Conference Date: Tuesday, March 12, 2024 Location: Miami, FL 1x1 investor meetings only Barclays 26th Annual Global Healthcare Conference Fireside Chat: Wednesday, March 13, 2024 at 4:05 p.m.
2024-03-06 12:36:04 - Zacks Investment Research
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
2024-02-29 16:57:00 - PRNewsWire
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST Interim clinical data will be presented by Aravindhan Veerapandiyan, M.D.
2024-02-27 21:45:19 - Seeking Alpha
REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript
2024-02-27 18:36:05 - Zacks Investment Research
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.38 per share a year ago.
2024-02-21 07:05:00 - PRNewsWire
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m.
2024-02-08 10:40:51 - Zacks Investment Research
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.
2024-02-08 05:51:04 - Zacks Investment Research
Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?
Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
2024-01-19 04:38:44 - Seeking Alpha
Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
REGENXBIO's stock has consistently underperformed, down 26% since May. The company released positive interim data from their Phase II trial for the treatment of wet age-related macular degeneration. The data showed a reduction in treatment burden and no cases of intraocular inflammation with the use of ABBV-RGX-314 gene therapy.
2023-11-08 22:26:02 - Seeking Alpha
REGENXBIO Inc. (RGNX) Q3 2023 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakola - Chief Medical Officer Vit Vasista - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Dane Leone - Raymond James Alec Stranahan - Bank of America Lisa Walter - RBC Capital Markets Brian Skorney - Baird Mani Foroohar - Leerink Partners Operator Good day, and thank you for standing by. Welcome to REGENXBIO's Third Quarter 2023 Earnings Conference Call.